Sanofi's rilzabrutinib was granted fast track designation by the FDA as a treatment for immune thrombocytopenia based on positive results from a Phase I/II trial. The company has already initiated a late-stage trial to further evaluate rilzabrutinib.
Sanofi's thrombocytopenia drug gains fast track tag
Sign up for ANA SmartBrief
Nursing news and information
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.